Hemorrhoid Drugs Market Outlook:
Hemorrhoid Drugs Market size was over USD 2.8 billion in 2025 and is estimated to reach USD 4.2 billion by the end of 2035, expanding at a CAGR of 4.7% during the forecast timeline, i.e., 2026-2035. In 2026, the industry size of hemorrhoid drugs is estimated at USD 2.9 billion.
The worldwide hemorrhoidal drugs market is continuously increasing, with a surge in the patient pool, readily affected by hemorrhoids. According to an article published by WebMD in June 2025, hemorrhoids are extremely common, particularly among the older population, and almost 1 in 20 people in the U.S. suffer from these, affecting more than half of people over 50 years. In addition, most people aged more than 45 years are also affected every year, with conditions such as analgesics, vasoconstrictors, and corticosteroids. Besides, the supply chain of hemorrhoid drugs comprises active pharmaceutical ingredients (APIs), which are readily manufactured in India and China. As per an article published by the USP Organization in April 2025, generic drugs cater to 90% of prescription volume in the U.S., while 43% of branded API originate from Europe.
Furthermore, medical devices, including hemorrhoid banding tools, are generally manufactured in regulatory infrastructures with imported components from East Asia and Europe. Besides, as per an article published by NLM in February 2024, internal hemorrhoids cater to an estimated 15% to 20% of the resting anal pressure and offer essential sensory information, thereby permitting the differentiation between liquid, gas, and solid. Meanwhile, the pharmaceutical preparation’s producer price index depicts a moderate growth in the market, based on the U.S. Bureau of Labor Statistics. According to its September 2025 data report, the PPI covers 69% of services, along with 17% of construction, as measured by 2017 Census revenue, thus suitable for the market’s development.
